RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes.
about
Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end productsIdentification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expressionSchwann cell interactions with axons and microvessels in diabetic neuropathy.A novel mechanism for antiglycative action of limonene through stabilization of protein conformation.Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathwayAdvanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36.Molecular mechanisms of diabetic vascular complicationsChelation therapy after the trial to assess chelation therapy: results of a unique trial.RAGE expression in human T cells: a link between environmental factors and adaptive immune responses.Inflammation in nonhealing diabetic wounds: the space-time continuum does matterUp-regulation of the receptor for advanced glycation end products in the skin biopsy specimens of patients with severe diabetic neuropathy.Protein kinase C and the development of diabetic vascular complications.Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf).Diabetes-related microvascular and macrovascular diseases in the physical therapy settingEffect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patientsAPPswe/Aβ regulation of osteoclast activation and RAGE expression in an age-dependent manner.Receptor for advanced glycation end products (RAGE) prevents endothelial cell membrane resealing and regulates F-actin remodeling in a beta-catenin-dependent mannerRegulation of RAGE for attenuating progression of diabetic vascular complications.Emerging drugs for renal failure.Amphoterin as an extracellular regulator of cell motility: from discovery to disease.2245G/A polymorphism of the receptor for advanced glycation end-products (RAGE) gene is associated with diabetic retinopathy in the Malaysian population.Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathyGene therapy for proliferative ocular diseases.Oxidative stress and stress signaling: menace of diabetic cardiomyopathy.Clinical study of advanced glycation end products in egyptian diabetic obese and non-obese patients.The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units.Intracranial aneurysm formation in type-one diabetes ratsN(epsilon)-(Carboxymethyl)lysine and Coronary Atherosclerosis-Associated Low Density Lipoprotein Abnormalities in Type 2 Diabetes: Current Status.Pharmacological treatment of diabetic neuropathic pain.HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation.Development of aldose reductase inhibitors for the treatment of inflammatory disorders.Receptor for advanced glycation end products (RAGE) and its ligands: focus on spinal cord injury.Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.Diabetes treatment in 2025: can scientific advances keep pace with prevalence?Receptor for advanced glycation end-products signals through Ras during tobacco smoke-induced pulmonary inflammation.RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells.Morroniside and loganin extracted from Cornus officinalis have protective effects on rat mesangial cell proliferation exposed to advanced glycation end products by preventing oxidative stress.Polymorphism 2184A/G in the AGER gene is not associated with diabetic retinopathy in Han Chinese patients with type 2 diabetesEffects of glycation of the model food allergen ovalbumin on antigen uptake and presentation by human dendritic cells.Propagation of the cardiac impulse in the diabetic rat heart: reduced conduction reserve.
P2860
Q26861308-A1ACE4FD-95AC-4772-93B0-C8B79ADC8111Q28590453-A2AB1EBF-919D-45E5-9A25-8A6A55F660A1Q30238727-16C60D79-940B-4391-BFE1-F92D597DDEDBQ30352232-2823AC92-5F0C-4C6F-902C-A0FB2656C98AQ30445160-CDDCDD24-C91B-490D-86D3-FD472D7FE492Q30518002-8744B923-BFDF-45AF-A003-5C50895A755AQ33558421-21B3017B-A92D-4A02-92D3-9336925E697CQ34171149-A298F2B5-3926-49BB-B0ED-6F7866B4D300Q34235391-376050AC-DF6A-4A93-8158-A9E2D5A4454CQ34326241-24F838C0-6C2B-4550-AE8B-29E8CC2C702CQ34346579-05ACE87C-CF93-4B30-84D9-8F71174E8186Q34570516-529F7220-AAA6-4EA1-A9EF-9F61C7DCBA52Q34786460-13AEE5B4-4E92-4E19-8116-E0011C9FC793Q34830905-CE68E1E9-42C0-4101-AAD6-12F1B3F91D51Q34960671-06E3ED11-9FA2-4EDD-8487-21CEA3399B31Q35077984-F6D606AC-52B4-4132-B531-5D0F84737CB0Q35266372-593BB7E3-82C9-4862-8002-FB712E777A1FQ35494903-E083729C-C6DF-4937-ACCC-58BE35DA74D5Q35602657-79AB76D1-6603-4DE8-A908-AB3B837C5470Q35661145-8D0681F0-B1C8-45EF-A3AB-A4A3AB487A32Q35682226-36A28707-0523-4FDD-A2F4-18C823C41A19Q35757154-979290F0-FCB9-4BE8-BD00-FF6FB54A6D2CQ35842653-6F85CE41-B05F-47EF-8E4E-05C529A67CFCQ36204491-B943A4F2-6EA9-4A2D-B128-6C84FAD0E95CQ36735682-02AF0BE3-E6BD-4720-A4B8-65408340FAEEQ36857011-96BD4691-FE2C-459D-A992-8BB041B11B40Q36976259-0FFF0FFB-A77F-4999-BC82-5D837C974315Q37036184-F93F7B19-BE7E-4683-8172-065A6BFF8BEDQ37858519-FFDBB4ED-ABE6-484F-AF87-9A91D09A1517Q37876420-94FF22EC-6E6E-488A-B750-5C0BA1444B3EQ38148786-BED3F803-4148-4CF0-8EA5-12B66718E2E1Q38234624-D560E6FD-5BA5-4555-A560-9AC929E699ECQ38359414-D13DCF75-FDBB-4185-AB24-F1A31357F1EAQ39513531-D13B1A04-122D-4B74-8D63-362E8E4B5D56Q39623825-BAF83D83-A1B9-47C0-900A-2305CDD72F7DQ39994864-8E4603AB-263B-4D1B-B987-2EC2EF022920Q40135652-20CF9E0C-BA46-480E-BB1A-9133BE141BFFQ42340230-2EDBF9A9-D2E2-4C81-A0F1-A2105838953EQ43239563-3A859610-ECF9-445C-B70B-D5C49743222EQ44489756-974E5A69-95CC-4006-B008-564C5C8C2619
P2860
RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
RAGE: a new target for the pre ...... ory complications of diabetes.
@ast
RAGE: a new target for the pre ...... ory complications of diabetes.
@en
RAGE: a new target for the pre ...... ory complications of diabetes.
@nl
type
label
RAGE: a new target for the pre ...... ory complications of diabetes.
@ast
RAGE: a new target for the pre ...... ory complications of diabetes.
@en
RAGE: a new target for the pre ...... ory complications of diabetes.
@nl
prefLabel
RAGE: a new target for the pre ...... ory complications of diabetes.
@ast
RAGE: a new target for the pre ...... ory complications of diabetes.
@en
RAGE: a new target for the pre ...... ory complications of diabetes.
@nl
P1476
RAGE: a new target for the pre ...... ory complications of diabetes.
@en
P2093
P304
P356
10.1016/S1043-2760(00)00311-8
P577
2000-11-01T00:00:00Z